- cafead   Jun 19, 2020 at 12:12: PM
via Pfizer’s tafamidis arrived in the U.S. in 2019 with a vastly discounted list price over rival transthyretin amyloidosis drugs. But its $225,000-a-year tag still seems too much for many heart patients.
article source
article source